@article{TLCR34128,
author = {Juan Ruiz-Bañobre and María C. Areses-Manrique and Joaquín Mosquera-Martínez and Alexandra Cortegoso and Francisco J. Afonso-Afonso and Noemí de Dios-Álvarez and Natalia Fernández-Núñez and Cristina Azpitarte-Raposeiras and Margarita Amenedo and Lucía Santomé and José Luis Fírvida-Pérez and Rosario García-Campelo and Jorge García-González and Joaquín Casal-Rubio and Sergio Vázquez},
title = {Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {6},
year = {2019},
keywords = {},
abstract = {The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time to the best of our knowledge the prognostic and predictive utility of the LIPI in a multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed the influence of the baseline LIPI on overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR) among 153 patients of a cohort of 188 advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Worse LIPI was significantly associated with shorter OS in univariate [hazard ratio (HR) =3.12, 95% confidence interval (CI), 2.12–4.60; P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/34128}
}